Psoriasis Longitudinal Assessment and Registry

(PSOLAR Trial)

Recruiting at 453 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Janssen Scientific Affairs, LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.

Research Team

Janssen Scientific Affairs, LLC Clinical Trial

Principal Investigator

Janssen Scientific Affairs, LLC

Eligibility Criteria

Inclusion Criteria

Have a diagnosis of psoriasis

Incident or prevalent users of Tremfya or an IL-17 inhibitor (eg, secukinumab, ixekizumab, brodalumab, bimekizumab) at the time of their enrollment. Incident users are defined as those participants starting treatment within 30 days before or after the enrollment visit and prevalent users are defined as those who are on treatment greater than 30 days prior to the enrollment visit

Ability to understand and sign an informed consent form

Treatment Details

Who Is Running the Clinical Trial?

Janssen Scientific Affairs, LLC

Lead Sponsor

Trials

165

Recruited

579,000+

Ricardo Attar

Janssen Scientific Affairs, LLC

Chief Executive Officer since 2008

PhD in Molecular Biology, University of Buenos Aires

Dr. Anastasia G. Daifotis

Janssen Scientific Affairs, LLC

Chief Medical Officer since 2023

MD